Review Article

Emerging Role of Dendritic Cell Intervention in the Treatment of Inflammatory Bowel Disease

Donglei Sun,1 Chenyang Li,1 Shuang Chen,2 and Xiaolan Zhang1

1Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang, China
2Department of Pediatrics and Department of Biomedical Science, Cedars Sinai Medical Center, Los Angeles, USA

Correspondence should be addressed to Xiaolan Zhang; xiaolanzh@126.com

Received 21 July 2022; Accepted 27 September 2022; Published 10 October 2022

Academic Editor: Hon W. Koon

Copyright © 2022 Donglei Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dendritic cells (DCs) are the most important antigen-presenting cells (APCs) of the immune system. These cells are implicated in IBD pathogenesis by genetics and microbial interactions and therefore may affect future therapeutic targets. In this review, the role of DCs in IBD treatment is discussed.

1. Introduction

Inflammatory bowel disease (IBD) is a costly, severe, and chronic inflammation of the gastrointestinal tract. Some of its examples include Crohn’s disease (CD) and ulcerative colitis (UC), which can be characterized by repeated phases of clinical relapses and remissions. However, the pathological mechanisms of IBD remain unclear. Innate and adaptive immune responses are known to play crucial roles in the pathogenesis and regulation of this illness [1]. Recent studies have focused on adaptive immune responses to explain the pathogenesis of IBD. In this regard, immunotherapy has emerged as a potentially attractive treatment target for IBD management.

Dendritic cells (DCs) are the most important antigen-presenting cells (APCs) of the immune system. These cells are implicated in IBD pathogenesis by genetics and microbial interactions and therefore may affect future therapeutic targets. In this narrative review, the role of DCs in IBD treatment is discussed.

2. Overview of IBD

IBD, including CD and UC, is a chronic form of inflammation of the GI tract [2] and is characterized by repeated phases of clinical relapses and remissions. This illness is a modern, incurable, autoimmune disease with low mortality.

2.1. The Pathogenesis of IBD. Genome-wide association studies in 100,000 patients with IBD revealed 200 loci associated with UC and CD [3, 4]. Most of the IBD-related loci are phenotypically dependent on intestinal microbes. Evidence of abnormal gut microbiota was documented in patients with IBD, but the potential pathogenic role of specific microorganisms remains unclear. More than 50% of IBD-related loci are associated with other autoimmune diseases, albeit with different effects [5]. Epidemiological data suggest an association between IBD and environmental factors such as smoking, drugs, geography, antibiotic use, social stress, and psychological elements [6].

2.2. Immunity and IBD. Although the aetiology of IBD has been studied extensively, its precise cause remains unclear. Innate immunity is thought to play an important role in the pathogenicity of IBD by initiating an adaptive immune response in response to specific antigens that are not yet understood [7]. Relevant immunological studies have focused on mucosal innate immune responses such as epithelial barrier integrity, innate microbial sensing, autophagy, and unfolded protein responses [8]. In patients with IBD,
the behavior of cell-mediating innate immunity and the expression and function of Toll-like receptors (TLRs) and NOD proteins are significantly altered [9]. The immune system produces an excessive and abnormal immune response to the host microflora of genetically susceptible individuals, thereby causing IBD.

2.3. Treatment of IBD. Treatment modalities include corticosteroids, aminosalicylates, immunomodulators, antibiotics, probiotics, and a series of unique novel agents. The use of antitumor necrosis factor monoclonal antibody (infliximab, adalimumab), recombinant anti-inflammatory cytokines, and related gene therapy has been explored, and discussions regarding dietary supplementation and heparin treatment have commenced. Meanwhile, more and more new biological drugs that target different inflammatory pathways have been approved for the treatment of IBD: golimumab, vedolizumab, ustekinumab, certolizumab pegol, natalizumab, et al. Although the pathogenesis of this disease is diversified, no curative treatment scheme has been proposed so far.

3. Immunological Properties of DCs

DCs are the most important APCs with significant phenotypic heterogeneity and functional plasticity. These cells initiate effective adaptive immune responses to eliminate the invading pathogens, thereby inducing immune tolerance towards harmless components to maintain immune homeostasis, activate naïve T cells, and stimulate proliferation.

3.1. Subgroups of DCs. Human DCs originate from hematopoietic stem cells from two sources: myeloid dendritic cells generated from myeloid stem cells through the stimulation of granulocyte-macrophage colony-stimulating factor, which has a common myeloid progenitor with monocytes and neutrophils, and plasmacytoid dendritic cells (pDCs) generated from lymphoid stem cells and have a common myeloid progenitor with T cells and nature killing cells [10]. Recent studies revealed that these two DC subsets perform different functions in innate and adaptive immune responses [11].

3.2. DCs and Immunity. Most DCs exist as immature cells that typically express low levels of major histocompatibility complex II and costimulatory molecules and therefore are inclined to modulate T cell differentiation towards T helper 1 (Th1), T helper 2 (Th2), T helper 17 (Th17), or regulatory T (Treg) cell [12]. Th2 response is often associated with immune tolerance and can be used for the treatment of autoimmune diseases. Immature DCs express high levels of pattern recognition receptors (PRRs) to promote their maturation and activation.

3.3. DCs and Autoimmune Diseases. DCs could inhibit the immune response by producing reactive and regulatory T cells and change the quality of T cell activation and differentiation [13]. The pathogenesis of autoimmune diseases is closely linked with the breakdown of DC-mediated tolerance. DC ablation in mice under steady-state conditions resulted in a spontaneous autoimmune disease, indicating that these cells are essential in preventing autoimmunity and maintaining immune tolerance [14]. Newly developed immunotherapies are based on the tolerogenic potential of regulatory DCs for the treatment of autoimmune diseases. Treatment of cytokine cocktails including interleukin (IL)-10 or TNF-α generated DCs that can induce profound tolerance in the mouse models of collagen-induced arthritis, autoimmune thyroiditis, and other autoimmune diseases [15]. In addition, human intervention with DCs can regulate the immune response of the body and is of great practical significance for autoimmune diseases [16].

4. DCs and IBD

In IBD, the immune system fails to maintain immune tolerance and drives the development of proinflammatory T cells that control the progression of this disease [17]. DCs have emerged as central players whose genetic susceptibility impacts the mucosal immune system and regulates the response to gut microflora by acting as a bridge between innate and adaptive immune responses.

4.1. DC as a Sentry. DC precursors migrate to the mucosa in the GI tract, where they become sentinels and sensors of the immune system. DCs serve as sentinels because they sample their environment, and they are highly effective at capturing and processing antigens [18]. These cells also act as sensors that identify the nature of the sampled antigens and discriminate between potentially harmless and hazardous antigens because of their highly expressed PRR molecules [19]. Even in the presence of innate immune stress, DCs can still be activated. Recently, pDCs were found to be related to IBD onset and are highly enriched in the inflamed colon of patients with IBD; this enrichment correlates with disease severity [20, 21]. pDC depletion impaired the gut barrier function and led to severe colitis in a Citrobacter rodentium-induced colitis model [22]. Various molecules involved in the different steps of DC differentiation, maturation, migration, and activation have become potential therapeutic targets for combating autoimmune responses [23].

4.2. Different DC Subgroups and IBD. IBD patients in remission have slightly lower numbers of mDC compared with healthy control. In acute flare ups, IBD patients experience a significant drop of DC that correlates with disease activity [24]. The mucosa of CD patients is characterized by an increase in pDCs and, notably, most of these pDC clusters are highly expressed in IL-1β [25]. The proportion of cultured peripheral blood pDCs expressing CD40 and CD86 was significantly higher in patients with UC and CD compared to controls, and they also secreted significantly more tumor necrosis factor TNF-α, IL-6, and IL-8 [26]. Experiments on mice have shown that in equilibrium, pDCs can migrate to specific tissues, such as lymph glands or the intestine, under the control of chemokine receptors [27]. CD11c+ DCs, a subtype of cDCs, were reduced by more than 75% in CD patients with and without inflammation in the ileum compared to controls, while these noninflamed areas showed no significant injury or inflammation, suggesting that loss of DCs may be a precursor to subsequent injury.
4.5. DC and Inflamatory Factors. Interferon (IFN)-γ-producing Th1 and IL-17-producing Th17 cells have been implicated in experimental colitis models and patients with IBD. The number of Th17 cells increases in inflamed patients with CD, and the IL-23 receptor variant associated with CD is damaged by the IL-23-induced Th17 effector function and works as a protective genetic variant [37]. Both are induced by a combination of IL-6 and TGF-β and promoted by IL-23 [38]. The involvement of Th17 cells and their signature cytokine IL-17A in intestinal inflammation has been extensively studied. Compared with that in a normal gut, high transcription levels of IL-17A were detected in the mucosa of CD and UC. Moreover, the inflamed IBD mucosa cultured in vitro produced higher levels of IL-17A than the control. The intrinsic involvement of receptor-interacting protein 2 (RIP2) in Th17 cell differentiation in a T cell appears as an essential mechanism for human chronic inflammatory diseases, including CD [39]. IL-23 in DCs is an essential component of the antimicrobial defence linking innate and adaptive immune responses. However, excessive or inappropriate amounts of IL-23 in DCs can result in the development of proinflammatory T cell responses, including the increased proliferation of effectors T cells, the decreased differentiation of FoxP3-positive regulatory T cells, and the appearance of IL-17 and IFN-γ-producing cells associated with chronic intestinal inflammation. By contrast, IL-23R polymorphism is associated with the risk of protection against IBD, and its functional characteristics lead to a reduction in T cell activation [40, 41]. MIR-10a, which is highly expressed in intestine DCs, regulates IBD pathogenesis by inhibiting the expression of IL-12/IL-23 p40 and NOD2 in DC and the functions of Th1 and Th17 cells in IBD [42].

5. DC-Related Intervention in the Therapies of IBD

Given the unique characteristics of DCs, which are found at the junction between innate and secondary antigen-specific immune responses, these cells can be used as a target for clinical intervention in patients with IBD. Different DC subgroups use different transcription factors and, therefore, can be applied as different immunomodulatory targets.

5.1. DC and TL1A in IBD. Some DC processes associated with IBD genetic susceptibility have been identified as potential therapeutic targets. For example, blocking the interaction between DCs and T cells can weaken the vital action of IL-23/IL-17 inflammatory pathways in IBD pathogenesis. Activated DCs express the tumor necrosis factor cytokine 1A (TL1A), which interacts with the death receptor (DR) 3 on the lymphocyte. Therefore, the modulation of TL1A-DR3 interaction may be a potential therapeutic target in several autoimmune diseases. Given that TL1A expression is increased in CD tissues, anti-TL1A antibodies can prevent the occurrence of colitis in mice. Spontaneous intestinal inflammation occurred in mice with overexpressed TL1A. Therefore, TL1A may be a feasible dendritic cell target in IBD. Anti-TL1A antibody could inhibit the activation of intestinal fibroblasts in the T cell transplantation model of chronic colitis and reduce the synthesis of collagen, thereby
ameliorating intestinal inflammation and fibrosis. The mechanism may be related to the suppression of the TGF-
631/Smad 3 signalling pathway [43].

5.2. DC and Pathway. B leukotriene receptor 1 (BLT1) signalling in DCs controls Th1 and Th17 differentiation and 2,4,6-trinitrobenzensulfonic acid- (TNBS-) induced colitis pathogenesis by regulating the production of proinflammatory cytokines, including IL-6, TNF-α, and IL-12 [44]. BLT1 regulates inflammatory cytokine release through Gαβγ subunit-phospholipase Cβ (PLCβ)-PKC pathway. Therefore, BLT1 antagonists can reduce the inflammatory cytokines produced by human peripheral blood DCs. These findings reveal the critical role of BLT1 in regulating adaptive immunity and TNBS-induced colitis and its potential as a drug target for adaptive immune-mediated IBD [45]. Rapamycin, an antibiotic that triggers autophagy by forming complexes with mTOR-inhibiting flavokawain B (FKB) 12, is commonly used to increase autophagy in cell culture. This drug has also been successfully applied to treat patients with severely refractory CD and has shown protective effects on mouse colitis models, thereby implying its promising utilization [46].

5.3. Other Interventions. Ghavami et al. [47] found that probiotics play an important role in DC immunomodulation by regulating the expression of costimulatory molecules, proinflammatory cytokines, and TLRs in DCs from patients with IBD. DCreg administered via vasoactive intestinal peptide (DC-VIP) injection could alleviate the clinical and histopathology severity of TNBS-induced colitis in mice and has been tested in different mouse colitis models treated with dexamethasone and 1α,25(OH)2D3 or pulsed with enterobacterial extract for colitis prevention [48]. Mesenchymal stem cells (MSCs) play useful roles in DSS-induced colitis through its Gal-3 dependence and its inhibition of DC inflammatory phenotype. Therefore, bone marrow MSC/ DC-targeted therapy is an effective treatment for chronic colitis [49]. However, the effects of bone marrow MSCs on colitis DCs have not been detected. Therefore, further research must focus on MSCs on DC phenotype and the function of colon infiltration in the pathogenesis of colitis induced by DSS. Suppression of pDC migration to colonic isolated lymphoid follicles abrogates the development of colitis [21]. Anti-inflammatory effects of Saccharomyces boulardii mediated by mDCs from patients with CD and UC [50]. Removal or diversion of gut-homing DC as well as T-cells is likely to be critical in prevention of gut focused inflammation in IBD [51].

6. Conclusion

DCs play important roles in the development and progression of IBD. A DC-related intervention provides a promising direction for IBD treatment. DCs could produce multiple proinflammatory and anti-inflammatory cytokines in response to environmental factors in patients with IBD and the mouse models of colitis. However, the following questions remain unclear: what are the differences in DC proper-
ties and mechanisms in CD and UC? Are the altered DC properties restricted to any subset or are all the subsets equally affected? Noninflammatory mucosal areas in patients with IBD show a proinflammatory cytokine environment that does not translate locally into macroscopic inflammation. Addressing these questions in future studies may expand our current knowledge of GI-DC to develop new therapies for IBD. Much research is needed to utilize DCs for IBD treatment.

Conflicts of Interest

All authors declare no conflicts of interest in this paper.

Authors’ Contributions

XZ takes responsibility for the integrity of the work as a whole, from inception to the published article. DS and CL designed the manuscript. DS wrote the initial manuscript. CL and SC wrote the manuscript. SC and XZ reviewed the manuscript. All authors contributed to the article and approved the submitted version. Donglei Sun and Chenyang Li are co-first author.

Acknowledgments

The authors would like to thank all the members of our department. The research was supported by the National Natural Science Foundation of China (no. 8187030159, 2018).

References

[1] A. Saez, R. Gomez-Bris, B. Herrero-Fernandez, C. Mingorance, C. Rius, and J. M. Gonzalez-Granado, “Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease,” International Journal of Molecular Sciences, vol. 22, no. 14, 2021.

[2] H. S. de Souza and C. Fiocchi, “Immunopathogenesis of IBD: current state of the art,” Nature Reviews Gastroenterology & Hepatology, vol. 13, no. 1, pp. 13–27, 2016.

[3] L. Jostins, S. Ripke, R. K. Weersma et al., “Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease,” Nature, vol. 491, no. 7422, pp. 119–124, 2012.

[4] J. Z. Liu, S. Van Sommeren, H. Huang et al., “Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations,” Nature Genetics, vol. 47, no. 9, pp. 979–986, 2015.

[5] M. Parkes, A. Cortes, D. A. van Heel, and M. A. Brown, “Genetic insights into common pathways and complex relationships among immune-mediated diseases,” Nature Reviews Genetics, vol. 14, no. 9, pp. 661–673, 2013.

[6] M. Lee and E. B. Chang, “Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues,” Gastroenterology, vol. 160, no. 2, pp. 524–537, 2021.

[7] Z. Kmiec, M. Cyman, and T. J. Sibbodia, “Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease,” Advances in Medical Sciences, vol. 62, no. 1, pp. 1–16, 2017.

[8] M. C. Choy, K. Visvanathan, and P. De Cruz, “An overview of the innate and adaptive immune system in inflammatory
bowel disease,” *Inflammatory Bowel Diseases*, vol. 23, no. 1, pp. 2–13, 2017.

[9] E. Layunta, E. Latorre, R. Forcén et al., “NOD2 modulates serotonin transporter and interacts with TLR2 and TLR4 in intestinal epithelial cells,” *Cell Physiol Biochem*, vol. 47, no. 3, pp. 1217–1229, 2018.

[10] S. Pühr, J. Lee, E. Zvezdova, Y. J. Zhou, and K. Liu, “Dendritic cell development-history, advances, and open questions,” *Seminars in Immunology*, vol. 27, no. 6, pp. 388–396, 2015.

[11] S. Campisano, A. La Colla, S. M. Echarte, and A. N. Chisari, “Th17 and Th17-like T cells in inflammatory bowel disease,” *Nature Immunology*, vol. 9, no. 1, pp. 128–145, 2019.

[12] A. Iwasaki and R. Medzhitov, “Control of adaptive immunity by the innate immune system,” *Nature Immunology*, vol. 16, no. 4, pp. 343–353, 2015.

[13] Y. Xiao, Q. Zou, X. Xie et al., “The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity,” *Journal of Experimental Medicine*, vol. 214, no. 5, pp. 1493–1507, 2017.

[14] S. K. Wculek, F. J. Cueto, A. M. Mujal, I. Melero, M. F. Krummel, and D. Sancho, “Dendritic cells in cancer immunology and immunotherapy,” *Immunity*, vol. 22, no. 7, pp. 1430–1431, 2020.

[15] J. N. Stoop, R. A. Harry, A. von Delwig, J. D. Isaacs, J. H. Robinson, and C. M. Hilkens, “Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses,” *Arthritis & Rheumatism*, vol. 62, no. 12, pp. 3656–3665, 2010.

[16] A. Waisman, D. Lukas, B. E. Clausen, and N. Yogev, “Dendritic cells as gatekeepers of tolerance,” *Seminars in Immunopathology*, vol. 39, no. 2, pp. 153–163, 2017.

[17] D. Bernardo, M. Chaparro, and J. P. Gisbert, “Human intestinal dendritic cells in inflammatory bowel diseases,” *Molecular Nutrition & Food Research*, vol. 62, no. 7, article e1700931, 2018.

[18] W. Jiang, W. J. Swiggard, C. Heufler et al., “The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing,” *Nature*, vol. 375, pp. 151–155, 1995.

[19] P. Valverde, S. Delgado, J. D. Martinez et al., “Molecular insights into DC-SIGN binding to self-antigens: the interaction with the blood group A/B antigens,” *ACS Chemical Biology*, vol. 14, no. 7, pp. 1660–1671, 2019.

[20] H. Liu, S. Dasgupta, Y. Fu et al., “Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD,” *BMC Immunology*, vol. 20, no. 1, p. 42, 2019.

[21] Y. Zhang, T. Yamamoto, S. Hayashi, and M. Kadowaki, “Suppression of plasmacytoid dendritic cell migration to colonic isolated lymphoid follicles abrogates the development of colitis,” *Biomedicine & Pharmacotherapy*, vol. 141, article 111881, 2021.

[22] S. Pöysti, S. Silojärvi, R. Toivonen, and A. Hänninen, “Plasmacytoid dendritic cells regulate host immune response to Citrobacter rodentium induced colitis in colon-draining lymph nodes,” *European Journal of Immunology*, vol. 51, no. 3, pp. 620–625, 2021.

[23] S. Sozzani, A. Del Prete, and D. Bosisio, “Dendritic cell recruitment and activation in autoimmunity,” *Journal of Autoimmunity*, vol. 85, pp. 126–140, 2017.

[24] D. C. Baumgart, D. Metzke, J. Schmitz et al., “Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells,” *Gut*, vol. 54, no. 2, pp. 228–236, 2005.

[25] V. Mitsialis, S. Wall, P. Liu et al., “Single-cell analyses of colon and blood reveal distinct immune cell signatures of ulcerative colitis and Crohn’s disease,” *Gastroenterology*, vol. 159, no. 2, pp. 591–608, 2020.

[26] D. C. Baumgart, D. Metzke, O. Guckelberger et al., “Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn’s disease and ulcerative colitis,” *Clinical & Experimental Immunology*, vol. 166, no. 1, pp. 46–54, 2011.

[27] S. Seth, L. Oberdörfer, R. Hyde et al., “CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions,” *The Journal of Immunology*, vol. 186, no. 6, pp. 3364–3372, 2011.

[28] R. Faleiro, J. Liu, D. Karunarathne et al., “Crohn’s disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cells,” *Clinical & Translational Immunology*, vol. 8, no. 7, article e010719, 2021.

[29] R. W. DePaolo, V. Abadie, F. Tang et al., “Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens,” *Nature*, vol. 471, no. 7337, pp. 220–224, 2011.

[30] H. Matsuno, H. Kayama, J. Nishimura et al., “CD103+ dendritic cell function is altered in the colons of patients with ulcerative colitis,” *Inflammatory Bowel Diseases*, vol. 23, no. 9, pp. 1524–1534, 2017.

[31] M. K. Magnusson, S. F. Brynjólfsson, A. Dige et al., “Macrophage and dendritic cell subsets in IBD: ALDH1 cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation,” *Mucosal Immunology*, vol. 9, no. 1, pp. 171–182, 2016.

[32] D. Kabelitz, D. Wesch, and H. H. Oberg, “Regulation of regulatory T cell: role of dendritic cells and toll-like receptors,” *Critical Reviews in Immunology*, vol. 26, no. 4, pp. 291–306, 2006.

[33] M. Luzentales-Simpson, Y. C. F. Pang, A. Zhang, J. A. Sousa, and L. M. Sly, “Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases,” *Frontiers in Cell and Developmental Biology*, vol. 9, article 612830, 2021.

[34] M. Hedl, A. Lahiri, K. Ning, J. H. Cho, and C. Abraham, “Pattern Recognition Receptor Signaling in Human Dendritic Cells is Enhanced by ICOS Ligand and Modulated by the Crohn’s Disease _ICOSLG_ Risk Allele,” *Immunity*, vol. 40, no. 5, pp. 734–746, 2014.

[35] A. Schlitzer, N. McGovern, P. Teo et al., “IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses,” *Immunity*, vol. 38, no. 5, pp. 970–983, 2013.

[36] T. R. Klauenhammer, M. Kleerbezem, M. V. Kopp, and M. Rescigno, “The impact of probiotics and prebiotics on the immune system,” *Nature Reviews Immunology*, vol. 12, no. 10, pp. 728–734, 2012.

[37] P. Di Meglio, A. Di Cesare, U. Laggner et al., “The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans,” *PLoS One*, vol. 6, no. 2, article e17160, 2011.

[38] L. Zhou, I. I. Ivanov, R. Spolski et al., “IL-6 programs TH17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways,” *Nature Immunology*, vol. 22, no. 11, p. 18, 2007.
K. Shimada, R. A. Porritt, J. L. Markman et al., “T cell intrinsic receptor interacting protein 2 regulates pathogenic T helper-17 cell differentiation,” *Immunity*, vol. 49, no. 5, p. 462, 2018.

M. F. Neurath, “IL-23 in inflammatory bowel diseases and colon cancer,” *Cytokine Growth Factor Reviews*, vol. 45, pp. 1–8, 2019.

J. Nie and Q. Zhao, “Lnc-ITSN1-2, derived from RNA sequencing, correlates with increased disease risk, activity and promotes CD4(+) T cell activation, proliferation and Th1/Th17 cell differentiation by serving as a ceRNA for IL-23R via sponging miR-125a in inflammatory bowel disease,” *Frontiers in Immunology*, vol. 11, p. 852, 2020.

W. Wu, C. He, C. Liu et al., “miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD,” *Gut*, vol. 64, no. 11, pp. 1755–1764, 2015.

H. Li, J. Song, G. Niu et al., “TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice,” *Pathology-Research and Practice*, vol. 214, no. 2, pp. 217–227, 2018.

L. A. Sacramento, F. Q. Cunha, R. P. de Almeida, J. S. da Silva, and V. Carregaro, “Protective Role of 5-Lipoxigenase during *Leishmania infantum* Infection Is Associated with Th17 Subset,” *BioMed Research International*, vol. 2014, Article ID 264270, 12 pages, 2014.

B. L. Finkbeiner, “Four-handed dentistry revisited,” *The Journal of Contemporary Dental Practice*, vol. 1, no. 4, pp. 25–33, 1999.

J. Zhao, H. Wang, H. Yang, Y. Zhou, and L. Tang, “Autophagy induction by rapamycin ameliorates experimental colitis and improves intestinal epithelial barrier function in IL-10 knockout mice,” *International Immunopharmacology*, vol. 81, article ???, 2020.

S. B. Ghavami, A. Yadegar, H. A. Aghdaei et al., “Immunomodulation and generation of tolerogenic dendritic cells by probiotic bacteria in patients with inflammatory bowel disease,” *International Journal of Molecular Sciences*, vol. 21, no. 17, p. 6266, 2020.

A. E. Anderson, D. J. Swan, O. Y. Wong et al., “Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4<sup>+</sup> T cells partly via transforming growth factor-β1,” *Clin Exp Immunol*, vol. 187, no. 1, pp. 113–123, 2017.

A. Nikolic, B. S. Markovic, M. Gazdic et al., “Intraperitoneal administration of mesenchymal stem cells ameliorates acute dextran sulfate sodium-induced colitis by suppressing dendritic cells,” *Biomedicine & Pharmacotherapy*, vol. 100, pp. 426–432, 2018.

S. Thomas, D. Metzke, J. Schmitz, Y. Dorffel, and D. C. Baumgart, “Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 301, no. 6, pp. G1083–G1092, 2011.

S. C. Knight, “Dendritic cell-T-cell circuitry in health and changes in inflammatory bowel disease and its treatment,” *Digestive Diseases*, vol. 34, no. 1-2, pp. 51–57, 2016.